TIRZEPATIDE — FACTS YOU SHOULD KNOW
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist. Clinical trials have demonstrated substantial improvements in body weight and several cardiometabolic measures in adults with obesity or overweight and weight-related complications.
DUAL HORMONE ACTION
Activates GIP and GLP-1 receptors to support multiple pathways involved in appetite regulation, glucose control and metabolism.
SIGNIFICANT WEIGHT IMPROVEMENT
Clinical trials show meaningful reductions in body weight across multiple doses.
SUPPORTS METABOLIC HEALTH
Associated with improvements in blood sugar control, blood pressure, lipids and other cardiometabolic risk factors.
HELPS REDUCE APPETITE
Supports a longer-lasting feeling of fullness, helping to reduce hunger and food cravings.
CLINICALLY STUDIED
Extensively evaluated in large, randomized, double-blind, placebo-controlled clinical trials in adults with obesity or overweight.
OVERALL WELLBEING
Improvements in weight and metabolic markers can contribute to better energy, mobility and quality of life.
CLINICAL TRIAL RESULTS — SURMOUNT-1
Mean Body Weight Reduction
Up to 22.5% mean reduction at 72 weeks with the 15 mg dose.*
Participants Achieving ≥20% Weight Reduction
62.9% of participants receiving the 15 mg dose at 72 weeks.*
Blood Pressure
Mean reduction of 8.1 mmHg in systolic blood pressure from baseline at 72 weeks with the 15 mg dose.*
Triglycerides
Mean reduction of 27.6% from baseline at 72 weeks with the 15 mg dose.*
Prediabetes — Return to Normoglycaemia
95.3% of tirzepatide-treated participants versus 61.9% receiving placebo at 72 weeks.†
Safety and Tolerability
The most common side effects were gastrointestinal, including nausea, diarrhoea, vomiting and constipation. They were generally mild to moderate and decreased over time.
Study design: Results from randomized, double-blind, placebo-controlled clinical trials in adults with obesity or overweight.
* At 72 weeks with the 15 mg dose.
† Among participants with prediabetes at baseline.